July 25, 2014 10:34 AM ET

Pharmaceuticals

Company Overview of Protein Sciences Corporation

Company Overview

Protein Sciences Corporation develops and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, an influenza vaccine; Panblok, a vaccine for pandemic influenza; FluNhance that is used as an additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine, which is used as an antigen for severe acute respiratory syndrome virus. It also provides baculovirus expression vector system for prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applications; GeneXpress, which provides protein production services; expresSF+ cells that optimizes protein production; and research ant...

1000 Research Parkway

Meriden, CT 06450

United States

Founded in 1983

Phone:

203-686-0800

Fax:

203-686-0268

Key Executives for Protein Sciences Corporation

Chief Executive Officer
Chief Medical Officer
Head of Government and Clinical Affairs
Executive Chairman and Global Head of Business Development
Age: 73
Compensation as of Fiscal Year 2014.

Protein Sciences Corporation Key Developments

Protein Sciences Corporation Receives Approval from FDA for 2014/15 Formulation of Flublok(R) Influenza Vaccine

Protein Sciences Corporation announced that the FDA has approved the company's strain change amendment for its seasonal influenza vaccine, Flublok. Every year influenza vaccine manufacturers must receive approval from the Agency for changes they make to the upcoming season's manufacturing process and product formulation, as the influenza vaccine is adapted annually. Early approval for Flublok will enable delivery on time to healthcare providers in the fall. This is especially important for those that rely on Flublok's unique properties for protection from the flu; namely, that the vaccine is egg-free, highly pure and triple the strength compared to conventional influenza vaccines.

Protein Sciences Corporation Announces Earlier Availability and Broader Distribution Coverage of its Modern, Egg-Free Flublok Influenza Vaccine for 2014/2015

Protein Sciences Corporation announced it will have more doses, earlier availability and broader distribution coverage of its modern, egg-free Flublok(R) Influenza Vaccine for the 2014/2015 season. Up to 500,000 doses of the vaccine will be manufactured, and the first doses will be available in September. ASD Specialty Healthcare and its Besse Medical and Oncology Supply divisions have been added as a distributor of Flublok. FFF Enterprises will continue to be a distributor.

Protein Sciences Corporation Presents at BIO Asia International Conference, Apr-08-2014 10:30 AM

Protein Sciences Corporation Presents at BIO Asia International Conference, Apr-08-2014 10:30 AM. Venue: Grand Hyatt, Tokyo, Tokyo, Japan.

Similar Private Companies By Industry

Company Name Region
Nature's Way Holding Company, LLC United States
Hesperion US, Inc. United States
Inotek Pharmaceuticals Corporation United States
Bluebonnet Nutrition Corporation United States
Hera Biomedical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 25, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Protein Sciences Corporation, please visit www.proteinsciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.